Please login to the form below
SOBI
This page shows the latest SOBI news and features for those working in and with pharma, biotech and healthcare.
Sobi’s Gamifant receives final rejection from CHMP for primary HLH
Sobi requested that the CHMP re-examine the application for Gamifant (emapalumab) as a treatment for of primary haemophagocytic lymphohistiocytosis (HLH) after the Committee initially rejected the drug in July. ... In the US, over 100 primary HLH
Latest news
-
GSK’s anti-BCMA drug leads crowded CHMP recommendations
Sobi has said it plans to request a re-examination by the CHMP and expects a subsequent opinion by the end of the year. ... The product has been able to make a substantial difference for a very vulnerable group of patients in the US,” said Guido Oelkers
-
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval ... Under the terms of the agreement, Sobi will offer a
-
FDA approves Bavarian Nordic’s smallpox and monkeypox vaccine
Earlier this year, AstraZeneca picked up a PRV from Sobi for $95m.
-
AstraZeneca buys FDA priority review voucher from Sobi
Picks up coveted voucher for $95m. AstraZeneca has paid Swedish biopharma company Sobi $95m in cash for an FDA priority review voucher (PRV), which could help cut four months off the ... Sobi gained the PRV during the acquisition of Novimmune’s
-
Sobi takes ownership of rare disease drug Gamifant for $518m
deal. “The acquisition of emapalumab and related assets is an important step in the transformation of Sobi in becoming a global leader in rare diseases,” says Guido Oelkers. ... We look forward to welcoming our new colleagues to join us in this
More from news
Approximately 12 fully matching, plus 14 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Heggie has lots of experience in the rare disease field, having served in senior roles at Shire, as a board member at Sobi and as CEO of German rare disease biotech
-
A rare opportunity
Sobi’s Neil Dugdale on how the UK’s approach to rare diseases is changing. ... An exciting time. For Neil's company Sobi it's certainly been a busy time this year.
More from intelligence
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
Most recently, Levin worked as the president of Sobi, where he was responsible for building the organisation and developing the strategic growth pillars of the company. ... Prior to Sobi, Levin held commercial leadership roles of increasing strategic
-
BMS appoints new commercial leader, Davies joins Eisai and more
Sobi appoints head of technical operations. Rare disease specialist company Sobi has appointed Anne Marie de Jonge Schuermans to front its new technical operations organisation. ... operations. She joins Sobi from Biogen, where she served as vice
-
Sobi poaches Pfizer’s Fredrick Wetterlundh
Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team. ... Guido Oelkers, CEO and president of Sobi, said: “His experience from the
-
Mereo BioPharma appoints head of patient access and commercial planning
Wills Hughes-Wilson joins the group from Sobi. London, UK-based Mereo BioPharma, has strengthened its team with the addition of Wills Hughes-Wilson, who joins the biopharma as its new ... In this role, Hughes-Wilson was responsible for Sobi’s
-
Sobi names Holly May VP of sales and marketing, US
Rare disease firm Sobi has appointed Holly May as its new vice president of sales and marketing for the US. ... May’s new role will see her lead the biopharma’s commercial team in bringing Sobi’s medicines to the country.
More from appointments
Approximately 9 fully matching, plus 6 partially matching documents found.
Latest from PMHub
-
The RARE Youth Revolution has begun
LifeArc. Sobi. “We are a proud supporter of RARE Youth Revolution and we are absolutely thrilled to have them as part of the Breaking Down Barriers project!
-
IGNIFI
Kyowa Kirin. Sobi. Theramex. Veriton Pharma. Vifor Pharma.
-
Say Communications
Novo Nordisk. Nutricia. Nutricia Global. SOBI. Target Ovarian Cancer. Trudell Medical.
The RARE Youth Revolution has begun
IGNIFI
Say Communications
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
-
Account Manager
-
Competitive salary with bonus and benefits
- Editorial Team Leader, Medical Communications, Oxford
-
Competitive Salary
- Graduate Business Analyst, Healthcare Communications – Pharma/ S...
-
Highly competitive salary
-
Head of Copy
-
£ competitive
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- GSK appoint Tony Wood as chief scientific officer
- Almirall and IRB Barcelona announce new research collaboration
- AstraZeneca’s Imfinzi and tremelimumab show unprecedented survival rate in liver cancer patients
- PM announces plans to lift England’s COVID-19 restrictions
- Expanding Access to High-Quality Healthcare
- FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
- Janssen’s Tremfya receives positive results for active psoriatic arthritis
- ARISE - a strategic healthcare communication planning process from Bedrock
- Pfizer and BioNTech start clinical trial for Omicron-based COVID-19 vaccine
- FDA restricts use of certain antibody treatments for COVID-19
- Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results
- Why pharma must get smart in its approach to customer engagement
- WHITE PAPER: Gender inequality—how COVID-19 impacted women
- FDA places partial clinical hold on three Gilead phase 3 trials for MDS and AML treatments
- Janssen’s Tremfya receives positive results for active psoriatic arthritis
- AstraZeneca’s oncology renaissance
PMHub
Spirit, an OPEN Health Company
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- Personalised medicine: driving a need for greater diversity in clinical trials
- Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
- Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
- With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
- Cervical Cancer Prevention Month
- In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...
